Budesonide Inhalation Suspension (Pulmicort Respules) Prescribing Information
Budesonide inhalation suspension is FDA-approved for maintenance treatment of asthma and prophylactic therapy in children 12 months to 8 years of age, administered via jet nebulizer only. 1
Indications and Patient Selection
Primary indication: Maintenance treatment of persistent asthma in children aged 12 months to 8 years 1
Key limitation: Not indicated for relief of acute bronchospasm or status asthmaticus—these require short-acting beta2-agonists and intensive measures 1
Dosing Recommendations
Dosing is stratified by previous asthma therapy 2, 1:
Initial Dosing Based on Prior Therapy
- Bronchodilators alone: 0.5 mg once daily OR 0.25 mg twice daily
- Inhaled corticosteroids: 0.5 mg once daily OR 0.25 mg twice daily, up to 0.5 mg twice daily
- Oral corticosteroids: 0.5 mg twice daily OR 1 mg once daily
- Symptomatic children not responding to non-steroidal therapy: 0.25 mg once daily may be considered
Dose Adjustment Strategy
If once-daily dosing provides inadequate control, increase total daily dose and/or divide into twice-daily administration. Once asthma stability is achieved, titrate downward to the lowest effective dose 1. Maximum benefit may require 4-6 weeks of treatment 1.
Age-Specific Dosing Guidelines
According to EPR-3 guidelines 2:
Children 0-4 years:
- Low dose: 0.25-0.5 mg daily
- Medium dose: >0.5-1.0 mg daily
- High dose: >1.0-2.0 mg daily
Note: Budesonide nebulizer suspension is the only ICS with FDA-approved labeling for children <4 years of age 2
Administration Requirements
Critical Administration Details
Use ONLY jet nebulizers—ultrasonic nebulizers are ineffective for suspensions 2, 1
Delivery method:
- Children <4 years: Require face mask that fits snugly over nose and mouth, avoiding nebulization in eyes 2
- Older children: May use mouthpiece
Compatibility: Budesonide suspension is compatible with albuterol, ipratropium, and levalbuterol nebulizer solutions in the same nebulizer 2
Post-treatment care: Wash face after each treatment to prevent local corticosteroid side effects 2
Available Formulations
Three strengths in single-dose ampules (Respules) 1:
- 0.25 mg/2 mL
- 0.5 mg/2 mL
- 1 mg/2 mL
Contraindications
Absolute contraindications 1:
- Primary treatment of status asthmaticus or acute asthma episodes requiring intensive measures
- Hypersensitivity to budesonide or any ingredient
Warnings and Precautions
Systemic Corticosteroid Effects
Hypercorticism and adrenal suppression may occur with high doses or in susceptible individuals 1. Deaths from adrenal insufficiency have occurred during transfer from systemic corticosteroids—taper slowly when transitioning 1.
Growth Effects
Monitor growth routinely (e.g., stadiometry) in all pediatric patients 1. Small but statistically significant reductions in growth velocity have been observed over 1 year, though effects may be transient 2, 1. The benefits of ICS therapy outweigh concerns about small, nonprogressive growth reduction 2.
Immunosuppression
Patients on immunosuppressant doses must avoid exposure to chickenpox or measles 1. If exposure occurs and the child lacks immunity, consult physician immediately. Potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections may occur 1.
Local Effects
Common local adverse effects 2:
- Oral thrush (candidiasis)
- Cough
- Dysphonia
Prevention: Rinse mouth/wash face after use; use spacer or valved holding chamber when applicable 2
Ocular Effects
Long-term use may increase risk of cataracts or glaucoma—consider regular eye examinations 1
Drug Interactions
CYP3A4 inhibitors (ritonavir, ketoconazole) can significantly increase systemic budesonide concentrations, potentially causing Cushing syndrome and secondary adrenal insufficiency 2
Special Populations
Pregnancy and Lactation
Budesonide is preferred during pregnancy (FDA Category B/TGA Category A) because more safety data exist compared to other inhaled corticosteroids 3, 4. No data indicate other ICS preparations are unsafe, so patients well-controlled on alternative ICS prior to pregnancy may continue 4.
Breastfeeding: Compatible—budesonide passes into breast milk but is considered acceptable 3
Hepatic Impairment
Monitor closely in patients with liver disease—budesonide undergoes extensive hepatic metabolism (85-95% first-pass), and impairment may lead to drug accumulation 1
Monitoring Parameters
Regular monitoring should include 1:
- Asthma symptom control
- Pulmonary function (when feasible)
- Growth velocity (stadiometry)
- Signs of hypercorticism or adrenal suppression
- Oral cavity examination for candidiasis
- Consideration of periodic eye examinations
Patient/Caregiver Education
Essential counseling points 1:
- Use at regular intervals (once or twice daily)—effectiveness depends on consistent use
- Not for acute symptom relief—always have rescue inhaler available
- Maximum benefit may take 4-6 weeks
- Do not stop therapy without physician guidance
- Wash face after each treatment
- Report decreasing effectiveness of rescue medications or significant lung function decline